KIT and gastrointestinal stromal tumor: It provides clinical benefit following the failure of imatinib treatment and it has been shown to be more active than first-line treatments in patients with wild-type GIST and KIT exon 9 mutations (all of which are relatively resistant to imatinib), as well as those with KIT exon 11 mutations.